TY - JOUR
T1 - Wilms' Tumor Gene 1 Transcript Levels in Leukapheresis ofPeripheral Blood Hematopoietic Cells Predict Relapse Risk inPatients Autografted for Acute Myeloid Leukemia
AU - Messina, Carlo
AU - Candoni, Anna
AU - Carrabba, Matteo G.
AU - Tresoldi, Cristina
AU - Sala, Elisa
AU - Tassara, Michela
AU - Crippa, Alessandra
AU - Peccatori, Jacopo
AU - Assanelli, Andrea
AU - Gattillo, Salvatore
AU - Bellio, Laura
AU - Fanin, Renato
AU - Ciceri, Fabio
AU - Bernardi, Massimo
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Autologous hematopoietic stem cell transplantation (ASCT) is a curative option alternative to allogeneic transplantation for patients with acute myeloid leukemia (AML). Relapse after ASCT can be due to contamination with leukemic blasts of autologous peripheral blood stem cells (PBSCs) collected by leukapheresis (LK). Identification and quantification of a minimal residual disease (MRD) marker in PBSCs could be relevant in determining the relapse risk after ASCT. High levels of the WT1 gene transcript in bone marrow of AML patients after treatment completion predict disease relapse. We evaluated WT1 transcript levels in autologous PBSC from LK used for ASCT in 30 consecutive AML patients in complete remission (CR) and established a correlation with clinical outcome. At diagnosis, all patients had WT1 overexpression. All patients were in morphological and genetic CR at the time of PBSC collection and before ASCT. Real-time quantitative PCR of WT1 was performed in samples of each LK, using TaqMan technology on RNA from mononucleated cells. The median WT1 transcript level in the PBSC graft (WT1-LK) of patients who relapsed was significantly higher than of those who did not relapse after transplantation (P
AB - Autologous hematopoietic stem cell transplantation (ASCT) is a curative option alternative to allogeneic transplantation for patients with acute myeloid leukemia (AML). Relapse after ASCT can be due to contamination with leukemic blasts of autologous peripheral blood stem cells (PBSCs) collected by leukapheresis (LK). Identification and quantification of a minimal residual disease (MRD) marker in PBSCs could be relevant in determining the relapse risk after ASCT. High levels of the WT1 gene transcript in bone marrow of AML patients after treatment completion predict disease relapse. We evaluated WT1 transcript levels in autologous PBSC from LK used for ASCT in 30 consecutive AML patients in complete remission (CR) and established a correlation with clinical outcome. At diagnosis, all patients had WT1 overexpression. All patients were in morphological and genetic CR at the time of PBSC collection and before ASCT. Real-time quantitative PCR of WT1 was performed in samples of each LK, using TaqMan technology on RNA from mononucleated cells. The median WT1 transcript level in the PBSC graft (WT1-LK) of patients who relapsed was significantly higher than of those who did not relapse after transplantation (P
KW - Acute myeloid leukemia
KW - Autologous stem cell transplantation
KW - Minimal residual disease
KW - Peripheral blood stem cell apheresis
KW - Real-time quantitative PCR
KW - Wilms' tumor gene 1
UR - http://www.scopus.com/inward/record.url?scp=84912531145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84912531145&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.06.017
DO - 10.1016/j.bbmt.2014.06.017
M3 - Article
C2 - 24954546
AN - SCOPUS:84912531145
VL - 20
SP - 1586
EP - 1591
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 10
ER -